Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DTQL30
|
|||
| Drug Name |
ASP2138
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Stomach cancer [ICD-11: 2B72] | Phase 1 | [1] | |
| Company |
Astelllas
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Claudin-18 (CLDN18) | Target Info | . | [1] |
| T-cell surface glycoprotein CD3 (CD3) | Target Info | . | [1] | |
| KEGG Pathway | Cell adhesion molecules (CAMs) | |||
| Tight junction | ||||
| Leukocyte transendothelial migration | ||||
| Hepatitis C | ||||
| NetPath Pathway | IL4 Signaling Pathway | |||
| Reactome | Tight junction interactions | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT05365581) A Phase 1/1b Study of ASP2138 in Participants With Metastatic or Locally Advanced Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma or Metastatic Pancreatic Adenocarcinoma Whose Tumors Have Claudin (CLDN) 18.2 Expression. U.S.National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.